Literature DB >> 20452100

Alzheimer disease pathology in cognitively healthy elderly: a genome-wide study.

Patricia L Kramer1, Haiyan Xu, Randall L Woltjer, Shawn K Westaway, David Clark, Deniz Erten-Lyons, Jeffrey A Kaye, Kathleen A Welsh-Bohmer, Juan C Troncoso, William R Markesbery, Ronald C Petersen, R Scott Turner, Walter A Kukull, David A Bennett, Douglas Galasko, John C Morris, Jurg Ott.   

Abstract

Many elderly individuals remain dementia-free throughout their life. However, some of these individuals exhibit Alzheimer disease neuropathology on autopsy, evidenced by neurofibrillary tangles (NFTs) in AD-specific brain regions. We conducted a genome-wide association study to identify genetic mechanisms that distinguish non-demented elderly with a heavy NFT burden from those with a low NFT burden. The study included 299 non-demented subjects with autopsy (185 subjects with low and 114 with high NFT levels). Both a genotype test, using logistic regression, and an allele test provided consistent evidence that variants in the RELN gene are associated with neuropathology in the context of cognitive health. Immunohistochemical data for reelin expression in AD-related brain regions added support for these findings. Reelin signaling pathways modulate phosphorylation of tau, the major component of NFTs, either directly or through β-amyloid pathways that influence tau phosphorylation. Our findings suggest that up-regulation of reelin may be a compensatory response to tau-related or beta-amyloid stress associated with AD even prior to the onset of dementia.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20452100      PMCID: PMC2990809          DOI: 10.1016/j.neurobiolaging.2010.01.010

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  25 in total

1.  APOE epsilon4 does not predict mortality, cognitive decline, or dementia in the oldest old.

Authors:  K Juva; A Verkkoniemi; P Viramo; T Polvikoski; K Kainulainen; K Kontula; R Sulkava
Journal:  Neurology       Date:  2000-01-25       Impact factor: 9.910

Review 2.  Histone acetylation and disease.

Authors:  S Timmermann; H Lehrmann; A Polesskaya; A Harel-Bellan
Journal:  Cell Mol Life Sci       Date:  2001-05       Impact factor: 9.261

3.  Trimming, weighting, and grouping SNPs in human case-control association studies.

Authors:  J Hoh; A Wille; J Ott
Journal:  Genome Res       Date:  2001-12       Impact factor: 9.043

4.  Direct binding of Reelin to VLDL receptor and ApoE receptor 2 induces tyrosine phosphorylation of disabled-1 and modulates tau phosphorylation.

Authors:  T Hiesberger; M Trommsdorff; B W Howell; A Goffinet; M C Mumby; J A Cooper; J Herz
Journal:  Neuron       Date:  1999-10       Impact factor: 17.173

5.  Reelin in plaques of beta-amyloid precursor protein and presenilin-1 double-transgenic mice.

Authors:  O Wirths; G Multhaup; C Czech; V Blanchard; G Tremp; L Pradier; K Beyreuther; T A Bayer
Journal:  Neurosci Lett       Date:  2001-12-28       Impact factor: 3.046

Review 6.  The evolution of cortical development. An hypothesis based on the role of the Reelin signaling pathway.

Authors:  I Bar; C Lambert de Rouvroit; A M Goffinet
Journal:  Trends Neurosci       Date:  2000-12       Impact factor: 13.837

7.  Reelin immunoreactivity in the adult primate brain: intracellular localization in projecting and local circuit neurons of the cerebral cortex, hippocampus and subcortical regions.

Authors:  Verónica Martínez-Cerdeño; María José Galazo; Carmen Cavada; Francisco Clascá
Journal:  Cereb Cortex       Date:  2002-12       Impact factor: 5.357

8.  Factors associated with resistance to dementia despite high Alzheimer disease pathology.

Authors:  D Erten-Lyons; R L Woltjer; H Dodge; R Nixon; R Vorobik; J F Calvert; M Leahy; T Montine; J Kaye
Journal:  Neurology       Date:  2009-01-27       Impact factor: 9.910

9.  Apolipoprotein E and Reelin ligands modulate tau phosphorylation through an apolipoprotein E receptor/disabled-1/glycogen synthase kinase-3beta cascade.

Authors:  Nobutaka Ohkubo; Young-Don Lee; Atsuyuki Morishima; Toshio Terashima; Satoshi Kikkawa; Masaya Tohyama; Masahiro Sakanaka; Junya Tanaka; Nobuji Maeda; Michael P Vitek; Noriaki Mitsuda
Journal:  FASEB J       Date:  2002-12-18       Impact factor: 5.191

10.  Reelin signaling antagonizes beta-amyloid at the synapse.

Authors:  Murat S Durakoglugil; Ying Chen; Charles L White; Ege T Kavalali; Joachim Herz
Journal:  Proc Natl Acad Sci U S A       Date:  2009-09-02       Impact factor: 11.205

View more
  51 in total

Review 1.  Neuroglialpharmacology: myelination as a shared mechanism of action of psychotropic treatments.

Authors:  George Bartzokis
Journal:  Neuropharmacology       Date:  2012-01-28       Impact factor: 5.250

2.  Reelin protects against amyloid β toxicity in vivo.

Authors:  Courtney Lane-Donovan; Gary T Philips; Catherine R Wasser; Murat S Durakoglugil; Irene Masiulis; Ajeet Upadhaya; Theresa Pohlkamp; Cagil Coskun; Tiina Kotti; Laura Steller; Robert E Hammer; Michael Frotscher; Hans H Bock; Joachim Herz
Journal:  Sci Signal       Date:  2015-07-07       Impact factor: 8.192

Review 3.  Alzheimer mechanisms and therapeutic strategies.

Authors:  Yadong Huang; Lennart Mucke
Journal:  Cell       Date:  2012-03-16       Impact factor: 41.582

4.  Overview and findings from the religious orders study.

Authors:  David A Bennett; Julie A Schneider; Zoe Arvanitakis; Robert S Wilson
Journal:  Curr Alzheimer Res       Date:  2012-07       Impact factor: 3.498

5.  Overview and findings from the rush Memory and Aging Project.

Authors:  David A Bennett; Julie A Schneider; Aron S Buchman; Lisa L Barnes; Patricia A Boyle; Robert S Wilson
Journal:  Curr Alzheimer Res       Date:  2012-07       Impact factor: 3.498

6.  Role of soluble epoxide hydrolase in age-related vascular cognitive decline.

Authors:  Jonathan W Nelson; Jennifer M Young; Rohan N Borkar; Randy L Woltjer; Joseph F Quinn; Lisa C Silbert; Marjorie R Grafe; Nabil J Alkayed
Journal:  Prostaglandins Other Lipid Mediat       Date:  2014-09-30       Impact factor: 3.072

Review 7.  More than cholesterol transporters: lipoprotein receptors in CNS function and neurodegeneration.

Authors:  Courtney Lane-Donovan; Gary T Philips; Joachim Herz
Journal:  Neuron       Date:  2014-08-20       Impact factor: 17.173

Review 8.  Pathways to neurodegeneration: mechanistic insights from GWAS in Alzheimer's disease, Parkinson's disease, and related disorders.

Authors:  Vijay K Ramanan; Andrew J Saykin
Journal:  Am J Neurodegener Dis       Date:  2013-09-18

9.  Biomarkers for the clinical evaluation of the cognitively impaired elderly: amyloid is not enough.

Authors:  Linda K McEvoy; James B Brewer
Journal:  Imaging Med       Date:  2012-06

10.  Malignant synaptic growth and Alzheimer's disease.

Authors:  Ehren L Newman; Christopher F Shay; Michael E Hasselmo
Journal:  Future Neurol       Date:  2012-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.